1 completed, 1 terminated, 1 unknown. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Terminated 1, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow catumaxomab: new trials by email Literature Review of catumaxomab trials Research Report on catumaxomab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine Catumaxomab - Bladder Cancer | Phase 1 / Phase 2 | Unknown | LintonPharm Co.,Ltd. | 161 | 2021-11-23 | 2023-02-13 |
| Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC Catumaxomab - Urinary Bladder Neoplasms | Phase 1 | Completed | Lindis Biotech GmbH | 34 | 2020-07-07 | 2026-10-16 |
| A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients catumaxomab - Epithelial Cancer Patients | Phase 1 | Terminated | Neovii Biotech | 16 | 2011-02-01 | 2013-07-02 |
Urinary Bladder Neoplasms (2) · Carcinoma (1) · Neoplasms (1) · Non-Muscle Invasive Bladder Neoplasms (1)
Lindis Biotech GmbH (1) · LintonPharm Co.,Ltd. (1) · Neovii Biotech (1)
Austria (1) · China (1) · Denmark (1) · Germany (1) · Spain (1)
Christian Dittrich, Prim.Univ.-Prof. (1) · Josep Tabernero, MD (1) · Morten Sorenesen, MD, Ph.D. (1) · R Oberneder, MD (1)
2019 (1)